Direct Healthcare Professional Communication (DHPC) on Forxiga® (Dapagliflozin) 5 mg: the medicinal product should no longer be used for the treatment of Type 1 Diabetes
2021.10.29
Active substance: dapagliflozin
Effective 25.10.2021 Forxiga (dapagliflozin) 5mg is no longer authorised for the treatment of patients with type 1 diabetes mellitus (T1DM) and should no longer be used in this population.
Download DHPC/Information letter , Download_VeroeffentlichtAm_EN